Aclaris Therapeutics, Inc. (0H8T.L) LSE
4.62
+0.095(+2.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aclaris Therapeutics, Inc.
Address
640 Lee Road
Wayne, PA 19087
United States of America (the)
Phone
484 324 7933
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Neal S. Walker | Co-Founder, Chief Executive Officer & Chairman | 965,550 | 1970 |
| Jesse W. Hall | Chief Medical Officer | 371,166 | 1974 |
| Roland Kolbeck | Chief Scientific Officer | 492,432 | 1964 |
| Hugh Davis | President, Chief Operating Officer & Director | 555,541 | 1960 |
| James Loerop | Chief Business Officer | 590,160 | 1965 |
| Kevin Balthaser | Chief Financial Officer | 631,710 | 1987 |
| Nina Samra | Senior Vice President of Clinical Operations | 0 | N/A |
| Jon Jacobsen | Senior Vice President of Chemistry | 0 | N/A |
| Matthew Rothman | General Counsel & Corporate Secretary | 0 | N/A |
| Steve Tucker | Executive Vice President of Project Leadership | 0 | N/A |
| William C. Roberts | Senior Vice President of Corporate Communications & Investor Relations | 0 | 1969 |
| Ajay Aggarwal | Senior Vice President of Clinical Development | 0 | N/A |
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
